Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026)

Revolution Medicines' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $172.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 1182.29% year-over-year to $172.6 million; the TTM figure through Mar 2026 stood at $306.6 million (up 195.11% YoY), while the FY2025 annual figure was $118.1 million, up 121.29% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $172.6 million, up from $74.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $172.6 million in Q1 2026, with the low at -$392.9 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $4.0 million (2023), against an average of -$37.1 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 1806.67% in 2022, then tumbled 6305.36% in 2024.
• Revolution Medicines' Cash from Investing Activities stood at -$7.1 million in 2022, then plunged by 5254.76% to -$380.4 million in 2023, then slipped by 3.29% to -$392.9 million in 2024, then jumped by 119.06% to $74.9 million in 2025, then soared by 130.52% to $172.6 million in 2026.
• Business Quant data shows RVMD's Cash from Investing Activities at $172.6 million in Q1 2026, $74.9 million in Q4 2025, and $24.8 million in Q3 2025.